In this study, we exhibited the pre-clinical therapeutic effectiveness of KPT-330, a selective inhibitor of XPO1, in cutaneous T-cell lymphoma (CTCL) cells. This evidence concerns the gene XPO1 and primary cutaneous T-cell non-Hodgkin lymphoma.